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A B S T R A C T
Aim: In view of the clinical importance of the adherence issues in schizophrenia management, a
consensus group of experienced local psychiatrists and nurse specialists gathered to outline a number of
consensus statements for clinicians to consider enhancing adherence in their patients.
Process: Prior to the consensus group meeting, three core members drafted eight statements on the issue
of adherence in schizophrenia. Using a modiﬁed Delphi method, published literature and published
guidelines regarding the management of schizophrenia were reviewed by the full panel during the group
meeting. After discussion and reﬂection from each individual member of the consensus group, the eight
statements were reworded and electronically voted on anonymously in two steps: acceptance on quality
of evidence and practicability in implementation.
Results: After modiﬁcations of the original statements, there was very high overall level of agreement
and acceptance (reaching international standard) on all the ﬁve areas of adherence within the eight
statements of the ﬁnalised statement.
Conclusions: The present consensus statements are the ﬁrst in Hong Kong to address systematically
adherence issues in schizophrenia management. They include areas on adherence assessment and
deﬁnition, treatment strategies in enhancing adherence, and treatment considerations at speciﬁc phases
of schizophrenia. They are tailored to be of practical utility in the local Hong Kong setting.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Adherence to treatment is essential for patients with schizo-
phrenia to achieve clinical remission. Despite the availability of
new drugs with improved efﬁcacy and safety proﬁles, poor
adherence remains a major issue in schizophrenia (Masand
et al., 2009). Studies have shown that up to 20–40% of patients
with schizophrenia fail to adhere to treatment (Chen et al., 2010;
Valenstein et al., 2006), and poor adherence may have signiﬁcant
impact on the clinical outcome of patients, leading to psychiatric* Corresponding author. Tel.: +852 2815 5111; fax: +852 2850 6556.
E-mail address: kymak@hku.hk (K.Y. Mak).
http://dx.doi.org/10.1016/j.ajp.2014.06.018
1876-2018/ 2014 The Authors. Published by Elsevier B.V. This is an open access articl
3.0/).complications, treatment resistance, and increased risk of relapse,
comorbidities or even suicide (Masand et al., 2009). As a result,
adherence should be assessed accurately and regularly so that
measures can be readily implemented in case of lack of adherence.
In Hong Kong, clinicians often fail to detect non-adherence (Hui
et al., 2006). There is no standardised procedure for the regular
assessment of patient adherence. Standardised treatment regi-
mens in enhancing adherence are also lacking. In view of this, a
consensus meeting was organised in Hong Kong as an attempt to
develop a local consensus to enhance adherence in the treatment
of schizophrenia, including proper clinical assessment, use of long-
acting injectable antipsychotics (LAIs), and various psychosocial
interventions. The essence of the consensus statements is to
provide a review of current knowledge and opinions concerninge under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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ments is evidence-based medicine, but interpretive comments
from the consensus group based on their expertise were provided
to back up the statements in case of inadequate or contradictory
evidence (Couetil et al., 2007). Comments from the consensus
group on the statements are also key to identify research gaps to
guide future research.
2. Methods
A meeting was held on 23rd July 2013 in Hong Kong, and the
consensus group included council members of the Hong Kong
Association of Psychosocial Rehabilitation and local clinical
healthcare professionals experienced in the management of
schizophrenia. Prior to the meeting, three core members of the
consensus group, based on clinical experience on the issue and
literature search, drafted 8 consensus statements. Five areas were
identiﬁed as important and relevant, viz.: (1) adherence assess-
ment; (2) deﬁning adherence; (3) pharmacological interventions;
(4) psychosocial interventions; and (5) treatment considerations at
speciﬁc phases of illness. The literature search was performed
using the PUBMED database with the following keywords:
‘schizophrenia and adherence’, ‘atypical antipsychotics and
adherence’, and ‘psychosocial intervention and adherence’. Only
those papers published after 2000 were included, and reports that
speciﬁcally address the adherence issue in schizophrenia were
included.
The modiﬁed Delphi method (Leung et al., 2013; Linstone and
Turoff, 2002) was abbreviated and employed for the formal face-to-
face expert focus ‘consensus group’ meeting. First, the core members
took turns to present the statements along with the associated
research evidence. After a comprehensive review and free discussion,
all (eleven) members of the consensus group voted anonymously on
each statement using electronic voting devices. With reference to the
methodology used by Ooi et al. (2010), each statement was rated
according to both (1) classiﬁcation of recommendation (based on
good, fair or poor scientiﬁc evidence to support or refute the
statement), and (2) practicability of recommendation in Hong Kong
(accept or reject with or without reservation). A consensus statement
was only accepted if at least 80% of the participants voted ‘‘A’’ or ‘‘B’’
for classiﬁcation of recommendation, and at least 65% voted ‘‘A’’or ‘‘B’’
for practicability (Table 1).
3. Results
After discussion, all eight consensus statements were ﬁnalised
and accepted by the consensus group. The statements were
categorised into ﬁve major parts. The ﬁrst two parts (statementsTable 1
The grading system for each consensus statement during the voting session.
Quality of evidence Classiﬁcation of recomme
I: Evidence obtained from at least
1 randomised controlled trial
A: There is good evidence
II-1: Evidence obtained from
well-designed control trials
without randomisation
B: There is fair evidence t
II-2: Evidence obtained from
well-designed cohort or
case–control study
C: There is poor evidence
but recommendation mad
II-3: Evidence obtained from
comparison between time or
places with or without intervention
D: There is fair evidence 
III: Opinion of respected authorities,
based on clinical experience
and expert committees
E: There is good evidence
Modiﬁed from the Canadian Task Force on the Periodic Health Examination [Barkun], 1–4) focused on the predictors, assessment and deﬁnition of
adherence, laying a foundation before addressing pharmacological
and psychosocial interventions for adherence in Parts 3 and 4
(statements 5–7). Part 5 (statement 8) addresses treatment
strategies at different phases of the course to enhance adherence
and clinical outcome of schizophrenia.
3.1. Adherence assessment
3.1.1. Statement 1: Patients with multiple complex predictors should
be identiﬁed as having a risky proﬁle for non-adherence
Voting on
1. Classiﬁcation of recommendation: A-55%, B-45%, C-0%, D-0%,
E-0%
2. Practicability of recommendation: A-36%, B-55%, C-9%, D-0%,
E-0%
After reviewing the various major references (Hui et al., 2006;
Oehl et al., 2000; Valenstein et al., 2006; Velligan et al., 2009), it
was agreed that ‘medication adherence’ is associated with four
main factors, which may be characterised as patient-, physician-,
treatment-, and environment-related (Oehl et al., 2000). Patient-
related factors mainly refer to demographic parameters. For
instance, patients of young age and male gender, patients with
comorbidities such as substance abuse and mood symptoms, and
patients with lack of formal education and poor illness insights
are more likely to be non-adherent (Hui et al., 2006; Valenstein
et al., 2006; Velligan et al., 2009). Health beliefs in terms of
patients’ perceptions towards antipsychotic medication, subjec-
tive wellbeing and quality of life are also correlated with
adherence (Oehl et al., 2000; Velligan et al., 2009). Physician-
related factors including therapeutic alliance and having a well-
structured treatment plan have an important impact on adher-
ence; whereas treatment-related factors including the beneﬁt/
risk ratio of medication and route of administration, and
environment-related factors such as the level of family/social
support are also associated with the level of adherence (Oehl et al.,
2000; Velligan et al., 2009).
In Hong Kong, previous local studies exploring antipsychotic
adherence in patients with schizophrenia concluded that
predictors of non-adherence included awareness of illness,
attitudes towards treatment, perceived beneﬁts of medication,
younger age, prescription with clozapine, and symptom severity
(Bressington et al., 2013a). It is therefore important that
healthcare professionals be advised to take note of patients’
medical history and their clinical/emotional status throughout
the course of illness, as well as supervise their treatmentndation Practicability of recommendation
 to support the statement A: Accept completely
o support the statement B: Accept with some reservation
 to support the statement
e on other ground
C: Accept with major reservation
to refute the statement D: Reject with reservation
 to refute the statement E: Reject completely
Ooi et al. (2010).
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adherence. The consensus group also considered ranking the risk
factors for non-adherence using a hierarchical approach accord-
ing to clinical practice.
3.1.2. Statement 2: Validated adherence rating scales should be
employed to assist the assessment of patient adherence in daily clinical
practice
Voting on
1. Classiﬁcation of recommendation: A-36%, B-55%, C-9%, D-0%,
E-0%
2. Practicability of recommendation: A-73%, B-27%, C-0%, D-0%,
E-0%
After reviewing related references (Kane, 2007; Velligan
et al., 2006, 2009), it was agreed that ‘assessment of adherence’
may be direct or indirect. Direct methods include observation of
medication intake and measurement of plasma drug levels and
biological markers. However, direct methods are burdensome
and impractical in routine clinical practice. Alternatively,
adherence may be assessed using indirect methods, which
include patient self-report and diary, pill counts, prescription
reﬁll data, and electronic monitors (Kane, 2007). In particular,
patient self-report in the form of rating scales is an efﬁcient and
cost-effective method of assessing adherence (Thompson et al.,
2000; Velligan et al., 2009). They are also regarded as easy to use
(Velligan et al., 2009), requiring a relatively short time to
complete.
There are a number of commonly used adherence rating scales,
including the Drug Attitude Inventory (DAI) (Hogan et al., 1983;
Thompson et al., 2000), the Medication Adherence Rating Scale
(MARS) (Thompson et al., 2000), and the Brief Adherence Rating
Scale (BARS) (Byerly et al., 2008). The DAI is the most commonly
used instrument that contains 10/30 items focusing on subjective
attitudes towards antipsychotics; it has good internal consistency.
The MARS is a 10-item self-report inventory which was based on
the DAI and the BARS is a clinician-administered adherence
instrument demonstrating good sensitivity and speciﬁcity in
identifying non-adherent outpatients.
All three scales have been validated with sound psychometric
properties, and they represent most of the components required in
the assessment of adherence. However, drawbacks on the use of
scales may include the potential to exaggerate the degree of
adherence (Velligan et al., 2006), and reduction of patients’
motivation to receive continuous drug therapy. After further
discussion, the consensus group agreed that in order to reﬂect the
true level of adherence accurately, clinical judgement and other
direct/indirect methods should be included.
3.2. Deﬁning adherence
3.2.1. Statement 3: The percentage of medication taken over a period
of time should be considered as a useful way of deﬁning adherence
Voting on
1. Classiﬁcation of recommendation: A-36%, B-46%, C-18%, D-0%,
E-0%
2. Practicability of recommendation: A-55%, B-36%, C-9%, D-0%,
E-0%
So far, there is no clear consensus in the literature regarding the
deﬁnition of medication adherence (Masand et al., 2009; Patel and
David, 2007; Velligan et al., 2006). Nonetheless, the percentage of
medication taken over a period of time seems to be the most
pragmatic method in deﬁning adherence (Velligan et al., 2009).Medication gaps during which no medication is taken by the
patient during a time period can also be used to assess adherence,
but dichotomised adherence scores (e.g. cessation of medication,
adherent/non-adherent) should be avoided if possible (Velligan
et al., 2009). Patients’ attitude towards medications is not a widely
supported method of deﬁning non-adherence (Velligan et al.,
2009).
The group concluded that in terms of the deﬁnition of ‘‘period’’
over which medication adherence should be assessed, the ﬁnite
length of a month or the follow up interval of clinical contact can be
used as the unit of time. Nevertheless, the interval of follow up
contacts may depend on the patients’ condition.
3.2.2. Statement 4: Deﬁnition of full, partial and non-adherence
should be cut-off as >80%, 50–80% and <50% of total prescribed
medication taken respectively
Voting on
1. Classiﬁcation of recommendation: A-18%, B-64%, C-18%, D-0%,
E-0%
2. Practicability of recommendation: A-45%, B-45%, C-9%, D-0%,
E-0%
Adherence is often reported as an all-or-nothing behaviour, and
clinicians tend to focus on non-adherent patients and often
underestimate the issue of partial adherence (Masand et al., 2009).
After reviewing the various references (Oehl et al., 2000; Velligan
et al., 2009; Weiden et al., 2004), the group preferred the deﬁnition
on ‘partial adherence’ as a patient taking some, but not all, of the
prescribed medication (Weiden et al., 2004), since in reality,
instead of complete discontinuation of treatment (non-adherence),
a majority of patients tend to be partially adherent to treatment at
any point in time.
The percentages regarding the level of adherence were derived
from an earlier expert consensus involving a panel of over 40 global
clinical experts. The 80% cut-off (for good adherence) is consistent
with that adopted in major research studies and reviews (Patterson
and Leeuwenkamp, 2008; Valenstein et al., 2006; Velligan et al.,
2009).
3.3. Pharmacological interventions
3.3.1. Statement 5: Patients with adherence issue should be given
informed choice including long acting injectable atypical
antipsychotics
Voting on
1. Classiﬁcation of recommendation: A-45%, B-55%, C-0%, D-0%,
E-0%
2. Practicability of recommendation: A-64%, B-36%, C-0%, D-0%,
E-0%
The group opined that because of the importance of
medication adherence to the disorder, patients should be
educated, and as far as possible, given the informed choice of
different types of treatment, including long-acting injectable
antipsychotics (LAIs). According to the references, the potential
beneﬁts of LAIs in addressing adherence issue include assurance
of medication delivery, leading to the immediate recognition of
non-adherence and clear appraisal of relapse that occurs despite
adequate pharmacotherapy. Other advantages include the
encouragement of regular contacts between patients and
clinicians, convenience for patients, achieving consistent plas-
ma drug levels, and continued medication coverage after a
missed dose (Kane, 2006; Nasrallah and Lasser, 2006; Patel et al.,
2009; Rainer, 2008; Zhornitsky and Stip, 2012).
Table 2
Adherence rate of different antipsychotics in patients with schizophrenia
(Lambert and Singh, 2006; Olivares et al., 2009).
Antipsychotics Percentage of patients
who stayed on medications
Oral 63.4%
Typical 34.0%
Risperidone 51.4%
Olanzapine 71.0%
Clozapine 81.3%
Conventional LAIs 65.3%
Risperidone LAI 81.8%
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LAIs resulting in a relative low usage rate (<40% and <10% of all
schizophrenic patients receive conventional depot injections and
atypical LAIs respectively). According to the panel, this is because
the patients’ conception that injections are only reserved for
difﬁcult-to-treat illness; the relatively high cost of atypical LAIs; a
sense of lack of self-control over medications; pain at the injection
site; and the doctors’ perception of the difﬁculty in dose titration
due to the long waiting time with delayed drug release (Kane,
2006; Patel et al., 2009; Taylor, 2009; Zhornitsky and Stip, 2012).
According to the data available (Haddad et al., 2009; Olivares
et al., 2009; Taylor, 2009), although LAIs may still exhibit similar
side-effects as oral antipsychotics such as extrapyramidal symp-
toms, prolactin-related adverse events, increased body weight and
body mass index, etc. (Buchanan et al., 2010; Fleischhacker, 2009;
Rossi et al., 2012), the use of LAIs over oral medications
nonetheless has been supported by global data indicating that aFig. 1. Clinical expert advice for management of sgenerally greater proportion of patients receiving LAIs stay on
treatment (Table 2) (Lambert and Singh, 2006; Olivares et al.,
2009).
With the recent available information on atypical LAIs, it was
agreed by the consensus group that atypical LAIs are more effective
than typical LAIs, with the latter better than oral atypicals which
are usually more effective than oral typicals. Therefore, the
consensus group concluded that LAIs should be considered a
treatment option for patients with adherence issues, as they can
facilitate adherence reducing the risk of relapse, not to mention
that there are indeed some patients who prefer injectable therapy
(Nasrallah and Lasser, 2006).
Nevertheless, not every patient will accept injectable therapy,
as a survey showed that about 30% of patients with schizophrenia
totally refused depot treatment (Heres et al., 2007). It is noted that
more exposure to LAIs may help increase patients’ conﬁdence in
using LAIs (Heres et al., 2007). Therefore, the consensus group
acknowledged that patient preference is an important factor in the
choice of treatment options, and psychiatrists are obliged to assist
their patients in making the right decision.
3.3.2. Statement 6: LAI atypical antipsychotics should be considered
as an option among indicated patients early in the course of illness in
improving adherence
Voting on
1. Classiﬁcation of recommendation: A-27%, B-64%, C-9%, D-0%,
E-0%
2. Practicability of recommendation: A-36%, B-55%, C-9%, D-0%,
E-0%chizophrenic patients with adherence issue.
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Perkins et al., 2008; Subotnik et al., 2011), non-adherence is a
signiﬁcant health concern in patients with early psychosis, and
studies have shown that nearly 60% of such individuals become
non-adherent after one year (Perkins et al., 2008). The reason for
the high non-adherence rates includes the notion that recovering
patients with early psychosis may not recognise the importance of
maintaining treatment and may therefore discontinue treatment
prematurely (Perkins et al., 2008). A recent clinical review on the
management of schizophrenia recommended that in patients with
early psychosis who demonstrate a poor adherence risk proﬁle
(Fig. 1), LAI atypical antipsychotics should be considered as a
treatment option in the early course of the disorder (Newton et al.,
2012). An open-label trial showed that the non-adherence rate in
patients receiving risperidone LAI is low, with over 70% of patients
completing treatment (Chue and Emsley, 2007).
During the discussion, it was pointed out that the relapse rate
within ﬁve years of the ﬁrst onset of illness is very high (Robinson
et al., 1999). Those with comorbid substance abuse problems or
with other ‘‘high-risk’’ factors (such as impulsive or violent
behaviour during relapses) may also beneﬁt from LAI treatment
(see Fig. 1). However, this latter point was based more on expert
opinions, and further evidence-based medicine is required to
support this conclusion.
The consensus group opined that the use of LAIs to enhance
adherence is not widely adopted during the early course of
schizophrenia in Hong Kong, as adherence in the long-term
outcome may not be considered as an important issue at this early
stage of the disorder. Presently many clinicians will only consider
prescribing LAIs when early-phase patients refuse to take oral
medications. Some will use LAIs when their patients engage in
disruptive behaviours which may present a danger to society.
Therefore, the consensus group agreed that clinicians should alter
their attitudes regarding LAIs as reserved only for chronic patients
or those with multiple relapses, and that LAIs should not be
considered as a punishment or deterrent treatment for dangerous
behaviour in acute patients. Actually, the use of LAIs in the early
course of illness may have signiﬁcant beneﬁts over oral
antipsychotics (Emsley et al., 2008). Nevertheless, such opinion
on the advantages of using LAIs in the early course of schizophrenia
requires more concrete local evidence.
3.4. Psychosocial interventions
3.4.1. Statement 7: Adjunctive psychosocial interventions should be
considered to be an integral part of the personalised care package to
improve adherence
Voting on
1. Classiﬁcation of recommendation: A-82%, B-18%, C-0%, D-0%,
E-0%
2. Practicability of recommendation: A-82%, B-18%, C-0%, D-0%,
E-0%
According to the literature, there are different forms of
psychosocial interventions that can be applied in the treatment
of schizophrenia, such as cognitive-behavioural therapy, family
therapy, social skills training, and cognitive remediation (Adams
et al., 2000; Bustillo et al., 2001; De Silva et al., 2013; Dixon et al.,
2009; Patterson and Leeuwenkamp, 2008). Supportive psychoso-
cial therapies may help alleviate residual symptoms and improve
social functioning and quality of life; and improved clinical
outcome in turn can encourage patients to adhere to treatment. An
important example is the randomised controlled trial when
patients with early psychosis were treated with antipsychotics
plus 12 months of psychosocial intervention, and the resultsshowed a signiﬁcantly lower risk of treatment discontinuation
than those treated with antipsychotics alone (Guo et al., 2010).
Another major randomised controlled trial demonstrated that a
signiﬁcantly greater proportion of patients with early psychosis
using the integrated treatment approach (pharmacotherapy,
psychosocial treatment, and psychoeducation) were adherent to
drug treatment when compared with those treated with anti-
psychotics alone (Valencia et al., 2012).
Cognitive behavioural therapy and coping skills training are
also considered effective since they speciﬁcally target the patient’s
perspectives of the illness and medication (Patel and David, 2007).
Besides, combining pharmacotherapy and psychosocial interven-
tions should be considered an integral part to improve adherence.
However, the consensus group opined that each form of
psychosocial therapy does vary in its therapeutic function, and
should thus be tailored to the individual patient.
3.5. Treatment considerations at speciﬁc phases
3.5.1. Statement 8: Phase-speciﬁc review of treatment regimes should
be conducted regularly for patients with adherence issue
Voting on
1. Classiﬁcation of recommendation: A-55%, B-45%, C-0%, D-0%,
E-0%
2. Practicability of recommendation: A-91%, B-9%, C-0%, D-0%,
E-0%
On the whole, the consensus group accepted that there should be
different treatment strategies for different phases of schizophrenia.
Presently, there is a trend that doctors used the same medications
(with adjustment in dosage) throughout the whole course of the
disorder, disregarding the physical and mental conditions of their
patients, or the potential long-term side effects of the medications.
In the acute phase, the major goals are to control psychotic
symptoms and reduce agitation (Lehman et al., 2004). It is
important that before prescribing the ﬁrst medication, clinicians
should review the medical histories and clinical status of their
patients. During this phase, dosing of antipsychotics may be
titrated as quickly as tolerated to the target therapeutic dose
(Lehman et al., 2004). It has also been suggested that the use of
adherence therapy (combining motivational and cognitive beha-
vioural techniques) just after an acute episode can be promising in
modifying patients’ beliefs about treatment to enhance medication
adherence (Schulz et al., 2013).
In the stabilisation phase, treatment should focus on reducing
the risk of relapse, supporting patients to resume a normal life, and
promoting the process of recovery. During this phase, the
additional use of supportive psychosocial interventions can be
less directive and more recovery oriented than in the acute phase.
For the stable or maintenance phase, the goal is to sustain
remission and improve patients’ quality of life. Regular monitoring
of adverse events and the use of antipsychotics that substantially
reduce the risk of relapse are recommended during this phase
(Lehman et al., 2004).
The consensus group agreed that such a ‘differential phase
treatment’ approach is good practice in the management of
schizophrenia, since it addresses the different treatment goals in
various phases of the disorder and the varied needs of the patient.
Regular review of treatment regimens to assess their effectiveness
is also crucial, since suboptimal symptom control and unpleasant
side effects may affect long-term adherence and the prognosis of
the disorder. Besides, such treatment review should not be limited
to clinical symptom assessment, but should also focus on other
aspects including patients’ quality of life, functional recovery, and
K.Y. Mak et al. / Asian Journal of Psychiatry 12 (2014) 163–169168adjustment to life in the community. Lastly, further evidence-
based studies in this area in the local setting are fully justiﬁed.
4. Conclusions
In Hong Kong, at least 26% of patients with schizophrenia are
non-adherent to their treatment (Hui et al., 2006), and it has been
reported that patients who discontinued medication are almost
ﬁve times more likely to relapse than patients who continued
taking medication (Kane, 2006). However, there is still a lack of
genuine awareness among a signiﬁcant number of local healthcare
professionals regarding patients’ adherence issues and the full
psychosocial consequence of non-adherence. According to a local
study in Hong Kong, medication management training pro-
grammes can be introduced to local community mental health
practitioners to modify their understanding of the illness. In
particular, avoiding persuasion, being person centred and empow-
ering service users with choices about treatment were identiﬁed as
effective approaches in managing non-adherence (Bressington
et al., 2013b).
The consensus group attempted to synthesise the scientiﬁc
evidence and clinical experience in Hong Kong into statements
addressing the adherence issue among patients with schizophre-
nia. The consensus generally complies with the key principles of
the National Institute for Health and Clinical Excellence (NICE)
Medicines Adherence guidelines, which include providing further
information and support for patients on the change of medication
regimen for the effective use of their medicines, respecting patient
treatment preference, and conducting regular review of treatment
regimens for patients in need of adherence support (NICE CG76,
2009). It is noteworthy that the statements are considered as
general clinical practice recommendations, as there are still some
other areas in the adherence issue to be explored (see Table 3). For
instance, although the risk factors/predictors of non-adherence are
listed, the hierarchical ordering is unclear at this stage. Though a
number of validated rating scales are available for assessing
adherence, the applicability of these scales in the local setting
should be further determined, together with individualised clinical
judgement. Local clinical research should be encouraged to shed
light on whether a ﬁnite or a ﬂexible interval is more practicable,
and whether the potential beneﬁts on the use of LAI atypical
antipsychotics to enhance adherence during the early course of
schizophrenia are relevant in Hong Kong.
Limitations of the present consensus statements include the
lack of data on the percentage increase in adherence due to
treatment with atypical LAIs, the clinical beneﬁts of using atypical
LAIs in ‘‘high-risk’’ patients, and the direct comparison of variousTable 3
Current research gaps in schizophrenia identiﬁed by the consensus group.
Topic Research gaps in schizophrenia
Risk factors of non-adherence Hierarchical ordering of risk factors in
assessing schizophrenia is still unclear
Non-adherence rating scales Applicability of these scales in the local
setting is not determined
Deﬁnition of medication adherence Practicability of a ﬁnite or a ﬂexible
interval over which medication
adherence should be assessed is still
unclear
LAI atypical antipsychotics Their use to enhance adherence during
the early course of schizophrenia or to
alleviate comorbidities associated with
schizophrenia is not yet clinically
proven
Differential phase treatment Effectiveness of this treatment
approach is not yet clinically proven in
the local settingatypical LAIs in terms of efﬁcacy and safety proﬁles. As a result,
statements 5 and 6 are partly based on expert opinions of
experienced professionals in their clinical practice.
In conclusion, the above consensus statements were essentially
based on the available evidenced-based data from global clinical
studies and management guidelines. These statements should be
monitored and updated regularly according to new ﬁndings, but
they can be considered as practical clinical recommendations in
the management of schizophrenia, especially for the less experi-
enced front-line professionals.
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